Outcome of magnetic resonance–Guided focused ultrasound surgery (MRgFUS) for FIGO class 1 fibroids. (February 2018)

• Record Type: Journal Article
• Authors: Mashiach, Roy; Inbar, Yael; Rabinovici, Jaron; Mohr Sasson, Aya; Alagem-Mizrachi, Aviva; Machtinger, Ronit
• Is Part Of: European journal of obstetrics, gynecology, and reproductive biology. Volume 221(2018)
• Page Start: 119
• Page End: 122
• Publication Date: 2018-02
• Subjects: MRgFUS -- Fibroids -- Submucousal -- Figo Class 1; Obstetrics -- Periodicals; Gynecology -- Periodicals; Reproductive health -- Periodicals; Gynecology -- Periodicals; Obstetrics -- Periodicals; Reproduction -- Periodicals; Obstétrique -- Périodiques; Gynécologie -- Périodiques; Reproduction -- Périodiques; Verloskunde; Gynaecologie; Voortplanting (biologie); Gynecology; Obstetrics; Reproduction; Electronic journals; Periodicals; Electronic journals; 618.05
• DOI: 10.1016/j.ejogrb.2017.12.025
• Languages: English
• ISSNs: 0301-2115

Abstract

Abstract: Objective: Intracavitary uterine fibroids and fibroids that distort the uterine cavity are associated with excessive vaginal bleeding and infertility. While intracavitary fibroids smaller than 4 cm are usually treated safely by operative hysteroscopy, larger fibroids may require multiple surgeries or more extensive surgery with possible damage to the integrity of the uterine wall. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) is a noninvasive approach for treating uterine fibroids, mainly the intramural type. We present the outcome of MRgFUS treatment for intracavitary fibroids (FIGO class 1) in cases that could not be treated by hysteroscopy due to either fibroid size or patient refusal. (Canadian Task Force II-1). Study design: A retrospective cohort study from a single tertiary referral center. A total of 68 patients were treated by MRgFUS for symptomatic uterine fibroids from January 2013 to December 2016. Six of them had FIGO class 1 fibroids. Adverse effects and short- and long-term outcomes (quality of life issues and need for additional surgical intervention) were assessed during ambulatory clinic visits and by phone interviews. Results: The mean ± SD fibroid volume on MRI screening was 86.3 ± 60.9 cm 3 . Six of those patients underwent the procedure (mean age 40.5 ± 5.6 years, range 33–48). The follow-up duration was 24.1 ± 12.0 months. Four patients were not interested in future fertility and did not undergo additional treatment, while the two who planned to conceive underwent another surgical intervention (one underwent operative hysteroscopy after reduction of fibroid size and the other underwent laparoscopic myomectomy). Conclusion: This preliminary study shows that MRgFUS can be a feasible treatment option for FIGO class 1 uterine fibroids. Shrinkage of fibroids by MRgFUS can obviate or facilitate subsequent surgical intervention in selected cases.